All In Biotech

NDA 022404 · Galt Pharms

Oravig

Miconazole · Buccal · Azole Antifungal

Last checked: Nov 20, 2026Latest source record: Feb 4, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

Apr 16, 2010

Approved uses

1

Original approval plus efficacy supplements

Registered trials

127

31 Phase 3, 11 recruiting

FAERS reports

0

1,973 serious, 260 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 8, 2026.

ORAVIG is indicated for the local treatment of oropharyngeal candidiasis (OPC) in adults. ORAVIG is an azole antifungal indicated for the local treatment of oropharyngeal candidiasis in adults.

Mechanism: Miconazole is an antifungal drug [see Microbiology (12.4)].

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ORAVIG · MICONAZOLE 50MG · TABLET, BUCCAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Miconazole" as an intervention, any sponsor and status, largest first.

All 127 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
FDA's data service returned an error (500). The numbers below may be missing or incomplete.
  • drug interaction238
  • drug ineffective133
  • international normalised ratio increased127
  • diarrhoea123
  • nausea106
  • off label use89
  • urinary tract infection87
  • dyspnoea84
  • rash81
  • fatigue76
  • pain74
  • pyrexia70

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200435
200525
200631
200745
200841
200943
201067
2011119
2012157
201364
201460
201578
2016101
2017182
2018225
2019178
2020144
2021120
2022126
2023159
2024130
2025106
2026100

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 287 on PubMed

Sponsor: Galt Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.